Cardiovascular Diseases, Heart Diseases, Coronary Disease, Diabetes Mellitus, Atherosclerosis, Cerebral Arteriosclerosis, Hypertension
Conditions
Brief summary
PLEASE NOTE: THIS STUDY IS ONLY ENROLLING PATIENTS CURRENTLY BEING TREATED AT BELAIR-EDISON FAMILY HEALTH CENTER. The purpose of this study is to compare the clinical effectiveness and cost effectiveness of two cardiovascular risk reduction programs - a comprehensive intensive (Cl) intervention with a less intensive (LI) intervention - in African American, and white low-income patients with known excessive cardiovascular disease risk.
Detailed description
BACKGROUND: The study is based on the premise that a community-based participatory research partnership model, using a team of an advanced practice nurse case manager, community health worker (CHW), and physician can be translated into urban community clinics and improve the quality of care and reduce disparities in cardiovascular health in minority and other underserved populations. Despite well-publicized guidelines on the appropriate management of cardiovascular disease (CVD) and type 2 diabetes, implementation of CVD risk-reducing practices remains poor. In spite of the known benefit of lowering low-density lipoprotein cholesterol (LDL-C) levels below 100 mg/dl in persons with existing heart disease, as many as 50 to 70 percent of eligible CVD patients are not placed on lipid-lowering therapy by their providers and from 20 to 80 percent of patients do not achieve the goals of therapy. The benefits of controlling high blood pressure (HBP) are well established, yet national rates of HBP control remain at only 31 percent despite decades of provider and patient education. In addition, it is well established that control of glycemia, hyperlipidemia, and blood pressure reduce the risk of vascular complications in people with diabetes, 75 percent of whom die from some form of heart or blood vessel disease. This randomized trial will compare the clinical effectiveness and cost effectiveness of a CI intervention with a LI intervention in African American, and white low-income patients with known excessive CVD risk. DESIGN NARRATIVE: Eligible patients with CVD or type 2 diabetes will be randomly selected from two urban federally funded community clinics and randomly assigned to receive either 1) a Cl intervention delivered by a nurse practitioner, a CHW, and the patient's physician, focusing on behavioral interventions to affect therapeutic lifestyle changes and medication adherence as well as the prescription and titration of medications or 2) a LI intervention providing feedback on CVD risk factors and guidelines to patients and their physicians. Outcomes will be measured at baseline and one and two years. It is hypothesized that a higher proportion of patients in the Cl intervention group will achieve the treatment goals for lipid, blood pressure, and diabetes management, lifestyle behaviors and utilization of antiplatelet agent, beta blocker, and angiotensin converting enzyme (ACE) inhibitor therapies and that the Cl intervention will be cost-effective. Secondary outcomes include assessment of the impact of the Cl intervention model on patients' satisfaction with care and health care utilization. The increase in the percentage of high-risk women and men who receive recommended secondary prevention therapies and achieve goal levels could potentially result in a marked decrement in annual CVD mortality and health disparities if applied within primary care settings to populations with the characteristics of the target groups for this study.
Interventions
Nutrition counseling, smoking cessation counseling, medication compliance counseling, exercise
Aspirin 81 mg q day
Oral medication
Oral medications, received 1-2 times per day
Sponsors
Study design
Eligibility
Inclusion criteria
* Currently receiving medical care at Johns Hopkins University * African American or Caucasian and have diagnosed CVD, defined as a prior myocardial infarction, revascularization procedure for coronary disease, ischemic heart disease, stroke, or have diagnosed type 2 diabetes and not receiving any therapy * Have either no LDL-C in their medical record during the 12 months prior to study entry or have an LDL greater than or equal to 100 mg/dl on or off lipid lowering pharmacotherapy * Have either no blood pressure recorded in their medical record during the 12 months prior to study entry or a BP greater than 140/90 mmHg or greater than 130/80 mmHg if the participant is diabetic or has renal insufficiency * If the participant is diabetic he or she has to either have no HbA1c recorded during the 12 months prior to study entry or HbA1c of 7 percent or greater
Exclusion criteria
* A serious life-threatening noncardiac comorbidity with a life expectancy of less than 5 years * A serious physician-recorded psychiatric morbidity that would interfere with the study * Sufficient neurological impairment that would interfere with the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HbA1c | Measured at 1 year | Fasting for 12 hour blood sample was measured in standardized lab |
| Low-density Lipoprotein Cholesterol | Measured at 1 year | Blood was drawn after a 12 hour fast and low density lipoprotein cholesterol was measured in a standardized lab |
| Systolic Blood Pressure | Measured at 1 year | Blood pressure measured with automatic blood pressure machine according to the guidelines of the American Heart Association. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patients' Satisfaction With Care and Health Care Utilization | Measured at 1 year | Patient satisfaction with care and healthcare utilization was measured with the Patient Assessment for Chronic Illness Care Scale (PACIC). The scores range from 0-5, with 5 being the most satisfied |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Comprehensive Intervention CI intervention will receive Behavioral: Lifestyle Changes, Nutrition counseling, smoking cessation counseling, medication compliance counseling, exercises, as well as pharmacologic agents | 261 |
| Less Intensive Intervention LI Arm: Participants will receive usual care from their physicians and a Less Intensive (LI) intervention of feedback on cardiovascular disease (CVD) risk factors and guidelines to patients and their physicians. | 264 |
| Total | 525 |
Baseline characteristics
| Characteristic | Less Intensive Intervention | Total | Comprehensive Intervention |
|---|---|---|---|
| Age, Continuous | 54.7 years STANDARD_DEVIATION 11.5 | 54.5 years STANDARD_DEVIATION 11.7 | 54.3 years STANDARD_DEVIATION 12 |
| Race/Ethnicity, Customized Black | 210 Participants | 417 Participants | 207 Participants |
| Race/Ethnicity, Customized White | 54 Participants | 108 Participants | 54 Participants |
| Sex: Female, Male Female | 187 Participants | 374 Participants | 187 Participants |
| Sex: Female, Male Male | 77 Participants | 151 Participants | 74 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 261 | 0 / 264 |
| serious Total, serious adverse events | 0 / 261 | 0 / 264 |
Outcome results
HbA1c
Fasting for 12 hour blood sample was measured in standardized lab
Time frame: Measured at 1 year
Population: Only the participants with a diagnosis of diabetes were assessed for this outcome measure
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Comprehensive Intervention Group | HbA1c | 8.3 percentage of hemoglobin | Standard Deviation 2.2 |
| Less Intensive Intervention Group | HbA1c | 8.2 percentage of hemoglobin | Standard Deviation 2.1 |
Low-density Lipoprotein Cholesterol
Blood was drawn after a 12 hour fast and low density lipoprotein cholesterol was measured in a standardized lab
Time frame: Measured at 1 year
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Comprehensive Intervention Group | Low-density Lipoprotein Cholesterol | 100.1 mg/dL | Standard Deviation 39.2 |
| Less Intensive Intervention Group | Low-density Lipoprotein Cholesterol | 110.6 mg/dL | Standard Deviation 36.8 |
Systolic Blood Pressure
Blood pressure measured with automatic blood pressure machine according to the guidelines of the American Heart Association.
Time frame: Measured at 1 year
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Comprehensive Intervention Group | Systolic Blood Pressure | 130.8 mmHg | Standard Deviation 20.7 |
| Less Intensive Intervention Group | Systolic Blood Pressure | 135.9 mmHg | Standard Deviation 20.5 |
Patients' Satisfaction With Care and Health Care Utilization
Patient satisfaction with care and healthcare utilization was measured with the Patient Assessment for Chronic Illness Care Scale (PACIC). The scores range from 0-5, with 5 being the most satisfied
Time frame: Measured at 1 year
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Comprehensive Intervention Group | Patients' Satisfaction With Care and Health Care Utilization | 2.9 units on a scale | Standard Deviation 0.9 |
| Less Intensive Intervention Group | Patients' Satisfaction With Care and Health Care Utilization | 1.8 units on a scale | Standard Deviation 1 |